Title: Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.
Journal: The Journal of pharmacology and experimental therapeutics 20120301
Title: New perspectives for the treatment of pulmonary hypertension.
Journal: British journal of pharmacology 20110501
Title: Direct fusion of subunits of heterodimeric nitric oxide sensitive guanylyl cyclase leads to functional enzymes with preserved biochemical properties: evidence for isoform specific activation by ciguates.
Journal: Biochemical pharmacology 20101201
Title: Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
Journal: Pharmacological research 20101101
Title: Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation.
Journal: Diabetes 20100801
Title: The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.
Journal: American journal of physiology. Lung cellular and molecular physiology 20091001
Title: Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation.
Journal: Cardiovascular research 20090715
Title: Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Journal: British journal of pharmacology 20090701
Title: NO- and haem-independent soluble guanylate cyclase activators.
Journal: Handbook of experimental pharmacology 20090101
Title: Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Journal: American journal of physiology. Heart and circulatory physiology 20081001
Title: Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Journal: Journal of clinical pharmacology 20070101
Title: Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage.
Journal: Kidney & blood pressure research 20070101
Title: Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20061201
Title: Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.
Journal: Molecular pharmacology 20060401
